Starpharma EV/EBITDA
Что обозначает EV/EBITDA в Starpharma?
EV/EBITDA Starpharma Holdings Limited является N/A
Какое определение для EV/EBITDA?
EV / EBITDA - это стоимость предприятия, деленная на прибыль до вычета процентов, налогов, обесценивания и амортизации. При помощи неё измеряется, насколько дорогой является акция, и она более действительна для сравнения компаний, чем для соотношения цены и прибыли. Она измеряет цену (в форме стоимости предприятия), которую инвестор платит в пользу денежного потока компании (в форме EBITDA).
Price to earnings ratios are impacted by a company's choice of capital structure - companies which raise money via debt will have lower P/Es (and therefore look cheaper) than companies that raise an equivalent amount of money by issuing shares, even though the two companies might have equivalent enterprise values. A sample case is when a company with debt were to raise money by issuing shares of stock, and then used the money to pay off the debt, this company's P/E ratio would shoot up because of the increased number of shares - although nothing about the fundamental value of the business has changed. EV / EBITDA is unaffected by capital structure as enterprise value includes the value of debt, and EBITDA is available to all investors (debt and equity) as it excludes interest payments on that debt. It is ideal for analysts and potential investors looking to compare companies within the same industry.
EV/EBITDA компаний в Health Care сектор на ASX по сравнению с Starpharma
Что делает Starpharma?
Starpharma Holdings Limited, a biopharmaceutical company, engages in the research, development, and commercialization of dendrimer products for pharmaceutical, life-science, and other applications worldwide. The company offers VivaGel, a non-antibiotic therapy for the management and prevention of bacterial vaginosis. It also develops VivaGel condom, an antiviral condom; and VIRALEZE, an antiviral nasal spray. In addition, the company develops DEP, a dendrimer drug delivery technology, including DEP docetaxel that is in Phase II clinical trials, DEP cabazitaxel that is in Phase II clinical trial, and DEP irinotecan that is in phase II clinical trials for the treatment of cancer; oncology programs, such as DEP radiopharmaceuticals, DEP HER-2 ADC, and DEP gemcitabine; DEP non-oncology candidates; and DEP AZD0466, which is in Phase I/II clinical trials to treat haematological tumours. The company was founded in 1996 and is headquartered in Abbotsford, Australia.
Компании с ev/ebitda похож на Starpharma
- AuMake International имеет EV/EBITDA из N/A
- Hydoo International имеет EV/EBITDA из N/A
- Damara Gold имеет EV/EBITDA из N/A
- Kairos Minerals имеет EV/EBITDA из N/A
- TVI Pacific имеет EV/EBITDA из N/A
- Aurion Resources имеет EV/EBITDA из N/A
- Starpharma имеет EV/EBITDA из N/A
- Diagnostic Medical Systems S.A имеет EV/EBITDA из N/A
- Xelpmoc Design and Tech имеет EV/EBITDA из N/A
- Just Plc имеет EV/EBITDA из N/A
- M&L имеет EV/EBITDA из N/A
- Takeaway.com NV имеет EV/EBITDA из N/A
- Just Eat Takeaway.com N.V имеет EV/EBITDA из N/A